Trial: NCT02383212

Disease Type: Solid Tumor
Status: Open

Trial Information

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death – 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients with Advanced Malignancies

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact:

Trial: NCT02465060

Disease Type: Solid Tumor
Status: Open

Trial Information

Molecular Analysis for Therapy Choice (MATCH)

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02240238

Disease Type: Solid Tumor
Status: Open

Trial Information

A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer

Click here for more information

This trial is available at:

Henry Lynch Cancer Center – Bergan
7500 Mercy Road, Suite 1300, Omaha, NE 68124
Phone: 402-393-3110
Fax: 402-393-4499

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145

For more information, please contact:

Trial: NCT02219711

Disease Type: Solid Tumor
Status: Pending

Trial Information

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Click here for more information

This trial is available at:

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

For more information, please contact:

Trial: NCT02981303

Disease Type: Solid Tumor
Status: Pending

Trial Information

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease

Click here for more information

This trial is available at:

Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463

For more information, please contact: